Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.68 |
| ▸ | MAPT | P10636 | 3/20 | 0.68 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.68 |
| ▸ | POLB | P06746 | 2/20 | 0.68 |
| ▸ | TSHR | P16473 | 5/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | F2 | P00734 | 1/20 | 0.52 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.46 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.46 |
| ▸ | CES2 | O00748 | 1/20 | 0.45 |
| ▸ | CES1 | P23141 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7645360 | 0.98 | ALDH1A1 (0.66) | ALDH1A1MAPTKMT2APOLBTSHR | |
| SCHEMBL4907232 | 0.85 | ALDH1A1 (0.76) | ALDH1A1MAPTKMT2APOLBTSHR | |
| SCHEMBL15317892 | 0.82 | TDP1 (0.61) | ALDH1A1MAPTKMT2APOLBLMNA | |
| SCHEMBL7371030 | 0.82 | ALDH1A1 (0.66) | ALDH1A1MAPTKMT2APOLBTSHR | |
| SCHEMBL4398385 | 0.81 | ALDH1A1 (0.59) | ALDH1A1MAPTKMT2APOLBTSHR | |
| SCHEMBL8981662 | 0.81 | ALDH1A1 (0.59) | ALDH1A1MAPTKMT2APOLBTSHR | |
| SCHEMBL6269137 | 0.81 | ALDH1A1 (0.70) | ALDH1A1MAPTKMT2APOLBTSHR | |
| SCHEMBL28121355 | 0.81 | ALDH1A1 (0.48) | ALDH1A1MAPTKMT2APOLBTSHR | |
| SCHEMBL5809526 | 0.81 | ALDH1A1 (1.00) | ALDH1A1MAPTKMT2APOLBTSHR | |
| SCHEMBL29102460 | 0.81 | ALDH1A1 (0.70) | ALDH1A1MAPTKMT2APOLBTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140044684-A1 | Methods And Compositions For Regulating Gene Expression | CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2014-02-13 | — | — | US | claimed |
| CN-102574992-A | Liquid crystalline polymer and molded article | POLYPLASTICS CO | 2012-07-11 | — | — | CN | claimed |
| US-20090304641-A1 | Methods and Compositions for Regulating Gene Expression | CHILDREN'S HOSPITAL BOSTON (US) | 2009-12-10 | — | — | US | claimed |
| WO-2007047706-A2 | METHODS AND COMPOSITIONS FOR REGULATING GENE EXPRESSION | CHILDREN'S HOSPITAL (US) | 2007-04-26 | — | — | WO | claimed |
| CN-1546473-A | Aliphatic amino substituted indole quinoline derivatives, their preparation method and pharmaceutical application | 中山大学 | 2004-11-17 | — | — | CN | claimed |
| CN-1083473-A | New imidazolium compounds and pharmaceutical composition thereof | SMITHKLINE BEECHAM CORP (US) | 1994-03-09 | — | — | CN | claimed |
| EP-0117080-B1 | SKIN TREATMENT COMPOSITION | UNILEVER PLC (GB) | 1992-04-08 | — | — | EP | claimed |
| US-20250129087-A1 | SALT CRYSTALS | INTRA-CELLULAR THERAPIES, INC. (US) | 2025-04-24 | — | — | US | disclosed |
| US-12281079-B2 | Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer | LEAD DISCOVERY CENTER GMBH (DE) | 2025-04-22 | — | — | US | disclosed |
| EP-4472638-A2 | SALT CRYSTALS | Intra-Cellular Therapies, Inc. (US) | 2024-12-11 | — | — | EP | disclosed |
| CN-119095589-A | Formulations of plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-118255866-A | Crystalline form of lanreotide salt, and preparation method and application thereof | 西交利物浦大学 | 2024-06-28 | — | — | CN | disclosed |
| US-20240115593-A1 | METHISOPRINOL COMPOSITIONS | PATEL REENA (IN) | 2024-04-11 | — | — | US | disclosed |
| WO-2003048136-A1 | CYCLOPROPYL HEXANE CONTAINING OXAZOLIDINONE ANTIBIOTICS AND DERIVATIVES THEREOF | MERCK & CO., INC. (US) | 2003-06-12 | — | — | WO | disclosed |
| CN-1298404-A | Inhibitors of phospholipase A2 | GENETICS INST (US) | 2001-06-06 | — | — | CN | disclosed |
| CN-1211574-A | Process for preparing benzodiazepine derivatives | DONG KOOK PHARM CO LTD (KR) | 1999-03-24 | — | — | CN | disclosed |
| EP-0117080-B1 | SKIN TREATMENT COMPOSITION | UNILEVER PLC (GB) | 1992-04-08 | — | — | EP | disclosed |
| EP-0196910-B1 | Benzo[a]phenazine derivatives | TAISHO PHARMACEUTICAL CO. LTD (JP) | 1991-01-02 | — | — | EP | disclosed |
| CN-85109752-A | Preparation triterpenoid organic acid ester and the method that contains the hypolipidemic agents of this compounds | — | 1986-12-17 | — | — | CN | disclosed |
| US-4254027-A | ESPECIALLY FOR AROMATIC POLYESTERS | IMPERIAL CHEMICAL INDUSTRIES LIMITED (GB) | 1981-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240115593-A1 | METHISOPRINOL COMPOSITIONS | INMT, MIF, CHRM1 | ALDH1A1 1349/4885MAPT 1175/4885KMT2A 2415/4885 |
| US-12281079-B2 | Quinoline derivatives, processes for their preparation and uses thereof for the treatment of cancer | AVPR2, AVPR1A, VHL | ALDH1A1 1304/4885MAPT 2941/4885KMT2A 426/4885 |
| US-20250129087-A1 | SALT CRYSTALS | SLC28A1, REN, NT5C3B | ALDH1A1 2041/4885MAPT 1114/4885KMT2A 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.